| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/20/2006 | WO2006039763A1 Vitamin d3 analogues for the prevention and treatment of bone disorders |
| 04/20/2006 | WO2006034468A3 Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders |
| 04/20/2006 | WO2006025979A9 Modulators of nuclear receptors |
| 04/20/2006 | WO2006023562A3 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
| 04/20/2006 | WO2006021888A3 Dihydrofolate reductase inhibition by epigallocatechin gallate compounds |
| 04/20/2006 | WO2006021803A3 Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
| 04/20/2006 | WO2006021655A3 Oxopiperidine derivatives, preparation and therapeutic use thereof |
| 04/20/2006 | WO2006021002A3 Compounds useful for inhibiting chk1 |
| 04/20/2006 | WO2006020156A3 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease |
| 04/20/2006 | WO2006019497A3 Sleep-inducing compounds and methods related thereto |
| 04/20/2006 | WO2006018708A3 Pyrrolidine derivatives as muscarinic receptor antagonists |
| 04/20/2006 | WO2006018609A3 Anti-inflammatory agents |
| 04/20/2006 | WO2006017726A3 Polysulfated glycosides and salts thereof |
| 04/20/2006 | WO2006016192A3 Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia |
| 04/20/2006 | WO2006014903A3 Compositions and methods of use for adam12 antagonists in treating disease |
| 04/20/2006 | WO2006013420A3 Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph) |
| 04/20/2006 | WO2006011631A3 Thiazole derivatives having vap-1 inhibitory activity |
| 04/20/2006 | WO2006010127A3 Therapeutic compound and treatments |
| 04/20/2006 | WO2006009755A3 Azaindoles modulating c-kit activity and uses therefor |
| 04/20/2006 | WO2006004658A3 Furanopyrimidines |
| 04/20/2006 | WO2006002971A3 Nucleic acids for the treatment of hmgb1-related pathologies |
| 04/20/2006 | WO2006000577A9 Lxr agonists to promote bone homeostasis |
| 04/20/2006 | WO2005120588A3 Peptides delivered to cell nuclei |
| 04/20/2006 | WO2005117882A8 Hydroxamic acid derivatives as metalloprotease inhibitors |
| 04/20/2006 | WO2005117859A3 Methods of diagnosing cardiovascular disease |
| 04/20/2006 | WO2005115398A3 Hiv integrase inhibitors |
| 04/20/2006 | WO2005115363A9 Method for treating skeletal disorders resulting from fgfr malfunction |
| 04/20/2006 | WO2005111039A3 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
| 04/20/2006 | WO2005096734A3 Non-imidazole heterocyclic compounds as histamine h3 receptor modulators |
| 04/20/2006 | WO2005094514A3 Heteroaryl piperidine glycine transporter inhibitors |
| 04/20/2006 | WO2005091804A3 Paramyxovirus family inhibitors and methods of use thereof |
| 04/20/2006 | WO2005091716A3 Annexin ii and uses thereof |
| 04/20/2006 | WO2005085867A3 Screening method for emulators of neural activity and digestive system using gpr35 |
| 04/20/2006 | WO2005084687A3 Boronic acid thrombin inhibitors |
| 04/20/2006 | WO2005082382A8 Formulations of thiomolybdate or thiotungstate compounds and uses thereof |
| 04/20/2006 | WO2005082357A8 Use of beta-lapachone for treating hematologic tumors |
| 04/20/2006 | WO2005079775A8 Method and preparation for reducing irritation and/or inflammatory reaction in human skin |
| 04/20/2006 | WO2005074912A3 Antiparasitic composition containing an organic amine salt of closantel |
| 04/20/2006 | WO2005072826A3 Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
| 04/20/2006 | WO2005066371A3 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 04/20/2006 | WO2005063296A3 Therapeutic combination for cognition enhancement and psychotic disorders |
| 04/20/2006 | WO2005063218A3 Pharmaceutical formulations of bisphosphonates |
| 04/20/2006 | WO2005062897A3 Polymorphs of ezetimibe and processes for the preparation thereof |
| 04/20/2006 | WO2005051489A3 Fast dissolving solid oral dosage forms of galanthamine |
| 04/20/2006 | WO2005051322A3 Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts |
| 04/20/2006 | WO2005041986A3 Use of biocompatible polymers for the preparation of a composition or a medical device |
| 04/20/2006 | WO2005041941A3 Valsartan containing formulation |
| 04/20/2006 | WO2005023255A3 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process |
| 04/20/2006 | WO2005016913A8 Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| 04/20/2006 | WO2004108088A3 Methods and compositions for interferon therapy |
| 04/20/2006 | WO2004051222A3 Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| 04/20/2006 | WO2004044164A3 Method for identifying risk of melanoma and treatments thereof |
| 04/20/2006 | US20060084819 Total synthesis of myriaporones |
| 04/20/2006 | US20060084809 Compounds as PDE IV and TNF-inhibitors |
| 04/20/2006 | US20060084803 Bicyclic pyridine and pyrimidine P38 kinase inhibitors |
| 04/20/2006 | US20060084795 Substituted 9a-n-[n'-(benzenesulfonyl)carbamoyl-aminopropyl]and 9a-n-[n'-(b-cya-neothyl) -n-[n'-(benzenesulfonyl)carbamoyl-y-aminopropyl]derivatives of 9-deoxo-9-dihydro-9a-aza- 9a-homoerithromycin a and 5-0-aza-homoerithronolide a |
| 04/20/2006 | US20060084759 Obtained by reacting phenolic alcohols with polyamines or polycarboxylates to form networks useful in artificial tissue and tissue engineering, such as artificial or synthetic cartilage, implantable |
| 04/20/2006 | US20060084704 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof |
| 04/20/2006 | US20060084703 Injectable liquid formulation of paracetamol |
| 04/20/2006 | US20060084702 (2S)-2-ethylphenylpropionic acid derivative |
| 04/20/2006 | US20060084701 Diagnosis and treatment of cervical and bladder cancer using hexyl 5-aminolevulinate as a photosensitizer; improved photochemotherapeutic properties; antineoplastic agents |
| 04/20/2006 | US20060084700 Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract |
| 04/20/2006 | US20060084699 Antagonists of the B2 receptor of bradykinin; analgesics; hyperalgesia and major algesia; cancer; nontoxic; industrial scale; 5-[[(2,4-dichloro-3-methylphenyl)sulphonyl]methylamino]-N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-N-methyl-pentanamide |
| 04/20/2006 | US20060084698 Methods for preparation and use of psorospermin analogs |
| 04/20/2006 | US20060084697 Pi3k antagonists as radiosensitizers |
| 04/20/2006 | US20060084696 FIBROSIS; ALZHEIMER'S DISEASE, Parkinson's disease, autoimmune disease, wound healing, osteoporosis; ANTIARTHRITIC AGENTS, anticholesterol agents |
| 04/20/2006 | US20060084695 atorvastatin lactone or pitavastatin lactone synergistically combined with a non-steroidal antiinflammatory agent; carciovascular disorders; P38 map kinase inhibitors |
| 04/20/2006 | US20060084694 Ligand-dependant activation of Nur77 and uses thereof |
| 04/20/2006 | US20060084693 e.g. 4-{2-[4-(5-cyano-1H-indol-3-yl)butylamino]ethoxy}benzofuran-2-carboxylic acid methyl ester; serotonin 5 HT1A and 5HT1D receptors agonist and antagonist, serotonin reuptake inhibitor; neuroleptic and hypotensive agent; |
| 04/20/2006 | US20060084692 Treatment of bipolar disorders and associated symptoms |
| 04/20/2006 | US20060084691 Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
| 04/20/2006 | US20060084690 Isoxazole derivatives |
| 04/20/2006 | US20060084689 Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| 04/20/2006 | US20060084688 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 04/20/2006 | US20060084687 N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy |
| 04/20/2006 | US20060084686 Methods of food intake management |
| 04/20/2006 | US20060084685 Ophthalmological use of roflumilast for the treatment of diseases of the eye |
| 04/20/2006 | US20060084684 Topically applicable pharmaceutical preparation |
| 04/20/2006 | US20060084683 Method for preventing the onset of asthma |
| 04/20/2006 | US20060084682 e.g. 5-{2-[6-(3,4-Dichloro-phenyl)-pyridin-2-yl]-1H-benzoimidazol-5-ylmethylene}-2-thioxo-thiozolidin; agonists of TPO receptor; non-peptide; thrombocytopenia is due to bone marrow, stem cell, or liver transplant, idiopathic thrombocytopenia purpura, myelodysplastic syndromes, aplastic anemia or leukemia |
| 04/20/2006 | US20060084681 Substituted pyrazoles, compositions containing such compounds and methods of use |
| 04/20/2006 | US20060084680 ((1S)-5-{2-[(3-methyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]ethoxy}-2,3-dihydro-1H-inden-1-yl)acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic diseases; hyperglycemia, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, hypertriglyceridemia, and insulin resistance |
| 04/20/2006 | US20060084679 Quinoline derivatives as H3R inverse agonists |
| 04/20/2006 | US20060084678 Methods for identifying and using MarR family polypeptide binding compounds |
| 04/20/2006 | US20060084677 2-sulfo, sulfanyl, sulfinyl, sulfonyl, or sulfamyl-5-substituted-6-sulfonyl quinolines; sulfiding, oxidation, dehalogenation or aralkylation of the 6-sulfonylquinoline; selective cyclooxygenase-2 inhibitors, analgesics; side effect reduction |
| 04/20/2006 | US20060084676 selective serotonin receptor antagonists for treating central nervous system disorders; chemical synthesis |
| 04/20/2006 | US20060084675 Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
| 04/20/2006 | US20060084674 Azaindole thiazolinones |
| 04/20/2006 | US20060084673 1,5-naphthyridine azolinone |
| 04/20/2006 | US20060084672 Method for modification of y-secretase activity through inhibition of Fkbp13 |
| 04/20/2006 | US20060084671 Process for the preparation of pure finasteride |
| 04/20/2006 | US20060084670 Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| 04/20/2006 | US20060084669 reaction of Isatoic anhydride with 2-pyrrolidone to form pegen-9-one-8 and easy crystallization for pure recovery then Clemmensen reduction of the pegenone intermediate to produce 1,2,3,9-tetrahydropyrrolo[2,1-b]chinazoline (deoxypeganine) |
| 04/20/2006 | US20060084668 Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard |
| 04/20/2006 | US20060084667 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| 04/20/2006 | US20060084666 Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
| 04/20/2006 | US20060084665 Quinolizinone compound and use thereof as HIV integrase inhibitor |
| 04/20/2006 | US20060084664 Substituted pyrido(1,2-A) pyrimidines and their use as NOS inhibitors |
| 04/20/2006 | US20060084663 Alkanoic acids, nitriles and amides substituted with a group containing benzene ring linked through a thiazolyl- or oxazolyl- phenyl group; e.g., {4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-2-propyl-phenoxy}-acetic acid; treating diabetes and atherosclerosis |
| 04/20/2006 | US20060084662 E.g., 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or the hydrochloride or oxalate; treating depression, anxiety disorder, and obsessive compulsive disorder. |